HSP90AA1 and liver cancer: A large-scale, multicenter clinical trial data showed that plasma Hsp90α could be used as an early diagnostic marker in the diagnosis of patients with liver cancer, and its diagnostic performance was better than that of AFP (sensitivity 92.7% and specificity 91.3%).